BRPI0315143B8 - composto, composição farmacêutica, e, uso de um composto - Google Patents

composto, composição farmacêutica, e, uso de um composto

Info

Publication number
BRPI0315143B8
BRPI0315143B8 BRPI0315143A BR0315143A BRPI0315143B8 BR PI0315143 B8 BRPI0315143 B8 BR PI0315143B8 BR PI0315143 A BRPI0315143 A BR PI0315143A BR 0315143 A BR0315143 A BR 0315143A BR PI0315143 B8 BRPI0315143 B8 BR PI0315143B8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
preparation
compounds
enantiomers
Prior art date
Application number
BRPI0315143A
Other languages
English (en)
Other versions
BRPI0315143B1 (pt
BR0315143A (pt
Inventor
Beliaev Alexander
Alexander Learmonth David
Manuel Vieira Araújo Soares Da Silva Patricio
Original Assignee
Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0223719A external-priority patent/GB2393958A/en
Application filed by Portela & Ca Sa filed Critical Portela & Ca Sa
Publication of BR0315143A publication Critical patent/BR0315143A/pt
Publication of BRPI0315143B1 publication Critical patent/BRPI0315143B1/pt
Publication of BRPI0315143B8 publication Critical patent/BRPI0315143B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

"composto, processo para a preparação dos (r) e (s) enanciômeros individuais ou misturas de enanciômeros e sais farmaceuticamente aceitáveis de um composto, composição farmacêutica, e, uso de um composto". são descritos compostos da fórmula (i) e um método para a sua preparação, em que x é ch~ 2~,o e s, e n é 1,2 ou 3, com a condição de que se x for ch~ 2~, n não é 1. os compostos possuem propriedades farmacêuticas potencialmente valiosas para o tratamento de distúrbios cardiovasculares, tais como hipertensão e falha cardíaca.
BRPI0315143A 2002-10-11 2003-10-10 composto, composição farmacêutica, e, uso de um composto BRPI0315143B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0223719A GB2393958A (en) 2002-10-11 2002-10-11 Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
GB0224306A GB2394223B (en) 2002-10-11 2002-10-18 Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation
PCT/GB2003/004430 WO2004033447A1 (en) 2002-10-11 2003-10-10 Imidazole derivatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase

Publications (3)

Publication Number Publication Date
BR0315143A BR0315143A (pt) 2005-08-16
BRPI0315143B1 BRPI0315143B1 (pt) 2017-02-14
BRPI0315143B8 true BRPI0315143B8 (pt) 2021-05-25

Family

ID=32031889

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0315143A BRPI0315143B8 (pt) 2002-10-11 2003-10-10 composto, composição farmacêutica, e, uso de um composto

Country Status (13)

Country Link
US (2) US7125904B2 (pt)
EP (5) EP1908760B1 (pt)
JP (1) JP4620464B2 (pt)
KR (1) KR101155159B1 (pt)
AU (1) AU2003271945B2 (pt)
BR (1) BRPI0315143B8 (pt)
CA (1) CA2501819C (pt)
GB (2) GB2432158B (pt)
MX (1) MXPA05003847A (pt)
PL (1) PL218537B1 (pt)
PT (1) PT103029B (pt)
RU (1) RU2332416C2 (pt)
WO (1) WO2004033447A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600709D0 (en) * 2006-01-13 2006-02-22 Portela & Ca Sa Drug combinations
GB0610804D0 (en) * 2006-05-31 2006-07-12 Portela & Ca Sa New crystal forms
RU2009126571A (ru) 2006-12-12 2011-01-20 Биал-Портела Энд Ка, С.А. (Pt) Каталитический способ асимметричной гидрогенизации
GB0700635D0 (en) * 2007-01-12 2007-02-21 Portela & Ca Sa Therapy
GB0701965D0 (en) * 2007-02-01 2007-03-14 Portela & Ca Sa Process
US20100093817A1 (en) * 2007-02-01 2010-04-15 Bial - Portela & Ca S.A. Compounds
GB0701966D0 (en) * 2007-02-01 2007-03-14 Portela & Ca Sa Process
WO2008115706A1 (en) * 2007-03-16 2008-09-25 Emory University Methods and compositions for treatment of drug addiction
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
GB0709695D0 (en) * 2007-05-21 2007-06-27 Portela & Ca Sa Process
TW200927740A (en) * 2007-11-13 2009-07-01 Bial Portela & Ca Sa Process
WO2009072915A1 (en) 2007-12-05 2009-06-11 Bial - Portela & Ca., S.A. New salts and crystal forms
AR070841A1 (es) * 2008-03-13 2010-05-05 Bial Portela & Ca Sa Proceso de hidrogenacion catalitica asimetrica
KR20110015412A (ko) 2008-03-19 2011-02-15 바이알 - 포르텔라 앤드 씨에이 에스에이 촉매적 비대칭 수소화
US8313984B2 (en) * 2008-03-19 2012-11-20 Ati Technologies Ulc Die substrate with reinforcement structure
AR071632A1 (es) 2008-05-06 2010-06-30 Bial Portela & Ca Sa Proceso catalitico para hidrogenacion asimetrica en la sintesis de inhibidores de la dopamina-beta-hidroxilasa"
EP3238738B1 (en) * 2008-11-10 2020-09-23 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
JP5574480B2 (ja) * 2009-03-12 2014-08-20 国立大学法人高知大学 アミノ基含有アセトン誘導体、及びそれを用いた炭素−炭素結合形成方法
CN104698749B (zh) * 2010-01-25 2019-11-19 罗门哈斯电子材料有限公司 包含含氮化合物的光致抗蚀剂
BR112013015864B1 (pt) * 2010-12-22 2021-11-09 Bial - Portela & C.A., S.A. Processo para purificar um composto de forma cristalina a de (r)-5-(2-benzilamino)etil)-1- (6,8-difluorocroman-3-il)-1h-imidazol-2(3h)-tiona
EP2726454B1 (en) 2011-06-29 2018-01-24 Bial-Portela & CA, S.A. Process
PT2822936T (pt) 2012-03-07 2021-12-02 Univ Of Delhi Derivados da aminoquinolina e suas utilizações
TR201815850T4 (tr) * 2012-11-14 2018-11-21 Bial Portela & Ca Sa Pulmoner arteryel hipertansiyonun ve akciğer hasarının tedavisinde kullanım için 1,3-dihidroimidazol-2-tion türevleri.
GB201316410D0 (en) 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
JOP20190050A1 (ar) * 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
US11434242B2 (en) 2017-12-04 2022-09-06 Bial—Portela & Ca, S.A. Dopamine-b-hydroxylase inhibitors
GB201810395D0 (en) 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
WO2020123699A1 (en) * 2018-12-11 2020-06-18 The Trustees Of Columbia University In The City Of New York Compounds and compositions that cause mycn and/or cmyc degradation and methods of use thereof
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH22522A (en) 1985-09-03 1988-10-17 Ciba Geigy Ag 3-amino-dihydro-1-benzopyrans and benzothiopyrans, their pharmaceutical compositions and method of using said compounds
EP0295401A3 (de) * 1987-04-30 1990-03-21 Wacker-Chemie Gmbh Verfahren zur Polymerisation von polaren Verbindungen
FR2619113B2 (fr) 1987-05-26 1991-06-28 Exsymol Sa Nouveaux produits de condensation de silanols, leurs preparation et application
US4868210A (en) * 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US5013854A (en) 1989-02-02 1991-05-07 Eli Lilly And Company Process for preparing acid halides
SE8904361D0 (sv) 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
ES2130135T3 (es) * 1990-01-11 1999-07-01 Upjohn Co Nuevos compuestos heterociclicos de 6,7,8,9-tetrahidro-3h-benz(e)indol con actividad terapeutica sobre el sistema nervioso central.
IT1241988B (it) 1990-06-15 1994-02-02 Sigma Tau Ind Farmaceuti 2- amminotetraline-6, 7-sostituite attive come immunomodulanti e composizioni farmaceutiche che le contengono
DD297249A5 (de) 1990-08-07 1992-01-02 Veb Mineralwollewerk Flechtingen Bereich F/E Mineralwolle,De Verfahren zur automatischen ueberwachung des aushaertegrades an materialbahnen
US5438150A (en) * 1994-04-26 1995-08-01 Syntex (U.S.A.) Inc. Process for making 1-benzocycloalkyl-1,3-dihydroimidazole-2-thione derivatives
US5538988A (en) * 1994-04-26 1996-07-23 Martinez; Gregory R. Benzocycloalkylazolethione derivatives
DE69531102T2 (de) * 1994-04-26 2004-04-29 Roche Palo Alto Llc, Palo Alto Benzocyclohexylimidazolthion-derivate
GB2290790A (en) 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
IT1271009B (it) 1994-09-13 1997-05-26 Zambon Spa Derivati del benzopirano e del benzotiopirano attivi sul sistema cardiovascolare
JPH08259572A (ja) * 1995-01-24 1996-10-08 Toyama Chem Co Ltd 新規なセファロスポリン誘導体またはその塩
IT1278045B1 (it) 1995-03-09 1997-11-17 Sigma Tau Ind Farmaceuti Uso di 2-amminotetraline-6,7-sostituite per la preparazione di composizioni farmaceutiche atte al trattamento dello shock, e di
IT1294931B1 (it) 1997-09-22 1999-04-23 Sigma Tau Ind Farmaceuti Derivati della 2-amminotetralina procedimento per la loro preparazione e composizioni farmaceutiche che li contengono, attive nella
SE9801726D0 (sv) 1998-05-15 1998-05-15 Astra Ab New process
CA2338328A1 (en) 1998-07-21 2000-02-03 Thomas Jefferson University Small molecule inhibitors of bcl-2 proteins
ES2224483T3 (es) 1999-04-19 2005-03-01 General Electric Company Aminas terciarias bis-sililicas.
US20010039343A1 (en) 2000-01-28 2001-11-08 Mulvihill Mark Joseph Process to intermediates for biologically active compounds
DZ3415A1 (fr) * 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
WO2002055112A2 (en) 2001-01-09 2002-07-18 Bristol Myers Squibb Co Polypodal chelants for metallopharmaceuticals

Also Published As

Publication number Publication date
EP1914233B1 (en) 2011-03-02
PL376224A1 (en) 2005-12-27
EP1911757A3 (en) 2008-05-28
GB2432159A (en) 2007-05-16
EP1408038A3 (en) 2004-04-21
EP1408038B1 (en) 2008-08-06
KR20050057647A (ko) 2005-06-16
AU2003271945B2 (en) 2009-12-17
PT103029A (pt) 2004-05-31
GB2432159B (en) 2007-06-27
PL218537B1 (pl) 2014-12-31
CA2501819A1 (en) 2004-04-22
PT103029B (pt) 2005-05-31
EP1908760A1 (en) 2008-04-09
BRPI0315143B1 (pt) 2017-02-14
EP1914233B8 (en) 2011-04-13
EP1908759A3 (en) 2008-04-16
EP1911757B1 (en) 2011-03-02
RU2005114021A (ru) 2005-11-10
GB2432158B (en) 2007-06-27
GB0702981D0 (en) 2007-03-28
BR0315143A (pt) 2005-08-16
EP1908759A2 (en) 2008-04-09
WO2004033447A1 (en) 2004-04-22
EP1908759B1 (en) 2012-03-21
GB0702982D0 (en) 2007-03-28
US7125904B2 (en) 2006-10-24
RU2332416C2 (ru) 2008-08-27
EP1914233A1 (en) 2008-04-23
EP1908760B1 (en) 2011-04-13
KR101155159B1 (ko) 2012-06-11
US20070015730A1 (en) 2007-01-18
JP2006507261A (ja) 2006-03-02
US7259271B2 (en) 2007-08-21
JP4620464B2 (ja) 2011-01-26
US20040142996A1 (en) 2004-07-22
AU2003271945A1 (en) 2004-05-04
GB2432158A (en) 2007-05-16
EP1911757A2 (en) 2008-04-16
EP1911757B8 (en) 2011-05-25
CA2501819C (en) 2012-09-04
MXPA05003847A (es) 2005-06-22
EP1408038A2 (en) 2004-04-14

Similar Documents

Publication Publication Date Title
BRPI0315143B8 (pt) composto, composição farmacêutica, e, uso de um composto
DE69830504D1 (de) Antithrombotische mitteln
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
ATE306261T1 (de) Antithrombosemittel
SE0302760D0 (sv) New compounds
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
BR0312464A (pt) Inibidores de tirosina quinases
BR0010555A (pt) Inibidores de neuraminidases
DE69919212D1 (de) Aromatische amiden
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
DE69931393D1 (de) Antithrombotische amide
BR0209431A (pt) Novos compostos de 4-anilinoquinolino-3-carboxamidas
BR0209948A (pt) Inibidores de fator inibitório de migração de macrófago e métodos para identificar os mesmos
NO20060847L (no) Substituert 2-aminotetralin til behandling av depresjon
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
BR0208811A (pt) Derivados de pirazol para tratamento de hiv
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
NO20020725L (no) Celleadhesjonsinhibitorer
BR0310077A (pt) Novos compostos e sua utilização
BR0007589A (pt) Inibidores da proliferação de células
BRPI0811275B8 (pt) derivado de 1,3-di-hidroimidazol-2-tiona como inibidor da dopamina-beta-hidroxilase, processo para a preparação do mesmo, composição farmacêutica, e, uso do mesmo
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
BR0309748A (pt) Derivados de n-acil piperidina e composição compreendendo os mesmos
BR0008302A (pt) Uso de um derivado de benzaldeìdo, derivado de benzaldeìdo, composição farmacêutica, e, processo para a fabricação da mesma

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/10/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2743 DE 01-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.